AFQ065
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smoking Abstinence
Conditions
Smoking Abstinence
Trial Timeline
Sep 1, 2006 → —
NCT ID
NCT00414752About AFQ065
AFQ065 is a phase 1 stage product being developed by Novartis for Smoking Abstinence. The current trial status is completed. This product is registered under clinical trial identifier NCT00414752. Target conditions include Smoking Abstinence.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00414752 | Phase 1 | Completed |
Competing Products
20 competing products in Smoking Abstinence